Copyright
©2012 Baishideng Publishing Group Co.
World J Cardiol. Mar 26, 2012; 4(3): 66-71
Published online Mar 26, 2012. doi: 10.4330/wjc.v4.i3.66
Published online Mar 26, 2012. doi: 10.4330/wjc.v4.i3.66
Table 1 Baseline clinical characteristics of patients with heart failure, comparing those with and without chronic obstructive pulmonary disease for June 2007 to June 2010 (SD)
Baseline features | HF patients with COPD | HF patients without COPD |
(n = 101) | (n = 682) | |
Age, yr | 75.8 (6.9)b | 71.3 (4.4) |
Gender (M/F, %) | 58/42 | 56/44 |
LVEF, % | 33.6 (10.7)b | 38.9 (4.8) |
Ischemic cause, % | 64.5 (4.8) | 68.9 (10.2) |
Duration of HF, yr | 7.2 (2.3) | 5.9 (4.2) |
Duration of COPD, yr | 6.9 (1.6) | ---- |
NYHA status | 2.6 (1.2) | 2.4 (1.4) |
FEV1/FVC ratio, % | 53.6 (7.4) | ---- |
Heart rate | 71.4 (12.8) | 73.4 (11.8) |
Blood pressure, mmHg | 125 (17.2)/76 (10.1) | 129 (11.4)/81 (9.3) |
eGFR | 57.4 (12.9) | 60.2 (13.5) |
BMI | 23.8 (5.3) | 24.6 (3.9) |
Table 2 Comorbidity in patients with heart failure, comparing those with and without chronic obstructive pulmonary disease for June 2007 to June 2010 n (%)
Condition | HF patients with COPD(n = 101) | HF patients without COPD(n = 682) |
Cardiovascular risk factors | ||
Diabetes | 17 (17) | 136 (20) |
Hypertension | 43 (43)b | 382 (56) |
Dyslipidemia | 24 (24) | 177 (26) |
Smoker | 57 (57)b | 164 (25) |
Ex-smoker | 31 (31)b | 136 (20) |
Cardiovascular disease | ||
Previous MI | 27 (27) | 198 (29) |
Angina | 49 (49) | 355 (53) |
Previous stroke | 20 (20) | 130 (19) |
Atrial fibrillation | 21 (21)b | 184 (27) |
Non-cardiovascular factors | ||
Cancer | 24 (24) | 177 (26) |
Depression | 31 (31)b | 143 (21) |
Table 3 Pharmacological treatments of patients with heart failure, comparing those with and without chronic obstructive pulmonary disease for June 2007 to June 2010 n (%)
Treatment | HF patients with COPD (n = 101) | HF patients without COPD (n = 682) |
Cardiovascular treatment | ||
Beta-blocker | 21 (22)b | 555 (81) |
ACE-inhibitor | 49 (49) | 382 (56) |
Angiotensin receptor blocker | 11 (11) | 82 (12) |
Spironolactone | 54 (54)b | 189 (28) |
Loop diuretic | 61 (61)b | 525 (77) |
Calcium channel blocker | 31 (31) | 184 (27) |
Amiodarone | 5 (5) | 41 (6) |
Aspirin | 60 (60) | 436 (64) |
Warfarin | 15 (15)b | 130 (20) |
COPD treatment | ||
Beta agonist | 61 (61)b | 20 (3) |
Inhaled anti-muscarinic | 27 (27)b | 6 (1) |
Inhaled steroid | 53 (53)b | 19 (3) |
Oral steroids | 24 (24)b | 2 (0.003) |
Table 4 Association between chronic obstructive pulmonary disease diagnosis and clinical outcomes in the patient cohort for June 2007 to June 2010
Outcome | COPD and HF | HF alone | Unadjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value |
HF hospitalization | 36 (36) | 143 (21) | 1.78 (1.49-2.11) | < 0.001 | 1.56 (1.4-2.1) | < 0.001 |
All-cause mortality | 29 (29) | 177 (26) | 1.07 (0.89-1.54) | 0.428 | 1.02 (0.77-1.5) | 0.225 |
Major CV events (non-fatal MI, stroke) | 19 (19) | 61 (9) | 1.34 (1.1-1.53) | < 0.001 | 1.23 (1.03-1.75) | < 0.001 |
CV death | 22 (22) | 155 (23) | 0.92 (0.68-1.06) | 0.357 | 0.96 (0.77-1.13) | 0.149 |
- Citation: O’Kelly N, Robertson W, Smith J, Dexter J, Carroll-Hawkins C, Ghosh S. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World J Cardiol 2012; 4(3): 66-71
- URL: https://www.wjgnet.com/1949-8462/full/v4/i3/66.htm
- DOI: https://dx.doi.org/10.4330/wjc.v4.i3.66